Last reviewed · How we verify
Administration of Metronidazole plus Amoxicillin
Metronidazole and amoxicillin together provide broad-spectrum antimicrobial coverage by inhibiting bacterial cell wall synthesis and DNA replication.
Metronidazole and amoxicillin together provide broad-spectrum antimicrobial coverage by inhibiting bacterial cell wall synthesis and DNA replication. Used for H. pylori infection eradication (as part of triple or quadruple therapy), Polymicrobial infections with aerobic and anaerobic bacteria, Dental and oral infections.
At a glance
| Generic name | Administration of Metronidazole plus Amoxicillin |
|---|---|
| Sponsor | University of Chile |
| Drug class | Antibiotic combination |
| Target | Bacterial DNA (metronidazole); bacterial cell wall/penicillin-binding proteins (amoxicillin) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Metronidazole is a nitroimidazole that disrupts bacterial DNA and is effective against anaerobic organisms and protozoa, while amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins. This combination is commonly used for polymicrobial infections where both aerobic and anaerobic coverage is needed, such as in H. pylori eradication or mixed bacterial infections.
Approved indications
- H. pylori infection eradication (as part of triple or quadruple therapy)
- Polymicrobial infections with aerobic and anaerobic bacteria
- Dental and oral infections
- Intra-abdominal infections
Common side effects
- Nausea
- Diarrhea
- Metallic taste (metronidazole)
- Abdominal discomfort
- Allergic reaction (amoxicillin)
- Headache
- Vomiting
Key clinical trials
- APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) (PHASE2)
- Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study
- Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
- Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans (PHASE3)
- NextGen - Clinical Implication of Next Generation Sequencing (PHASE4)
- Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease (NA)
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
- Tailored Therapy for Clarithromycin-Resistant H. Pylori (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: